Navigation Links
Allegheny General Hospital Study Suggests Use of Image Guided Intensity Modulated Radiation Therapy Reduces Risk of Impotency in Men Needing Radiation after Prostate Cancer Surgery
Date:11/2/2010

PITTSBURGH, Nov. 2, 2010 /PRNewswire-USNewswire/ -- Men battling prostate cancer who receive Image Guided Intensity Modulated Radiation Therapy after undergoing prostatectomy have an excellent chance of retaining sexual function, according to a study by Allegheny General Hospital (AGH) cancer specialists presented this week at the annual meeting of the American Society for Therapeutic Radiation and Oncology in San Diego.

Each year in the United States about 200,000 men are diagnosed with prostate cancer. It is the second most common cancer among men, second only to skin cancer.  Most men with prostate cancer are over age 65, and the disease disproportionately strikes African-American men.

"Any cancer diagnosis can impact quality of life, but a prostate cancer diagnosis can be particularly difficult for men because impotence is a common side effect of treatment," said Russell Fuhrer, MD. "While recent improvements have made loss of potency less common after prostate cancer therapy, men must still take this complication into account as they decide on a treatment plan."

The AGH study, "Preservation of Sexual Function After High-Dose Post Prostatectomy Image Guided Intensity-Modulated Radiation Therapy (IMRT)," looked at 33 patients who underwent prostate removal surgery using open or robotic nerve-sparing techniques, followed by Image Guided IMRT radiotherapy.

Image Guided IMRT is an advanced type of radiotherapy in which computer-controlled linear accelerators direct radiation precisely to the tumor, sparing surrounding healthy tissues. Used extensively to treat prostate cancer, Image guided IMRT allows a higher, more focused and effective dose of radiation to the tumor.

Before radiotherapy, the men assessed their sexual function using a self-administered questionnaire called SHIM, Sexual Health Inventory for Men. For men who qualified as potent, researchers again used the SHIM test to measure their potency after radiotherapy
'/>"/>

SOURCE West Penn Allegheny Health System
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pennsylvania Agriculture Department Issues Quarantine for Allegheny County Horse Stable
2. Allegheny General Hospital Performs First Liver Transplant
3. Accuray Hires General Manager for the Asia Pacific Region
4. General Dynamics Awarded Contract to Outfit and Transition U.S. Army Medical Facilities
5. Lotus Pharmaceuticals Retains Sichenzia Ross Friedman Ference LLP as General Legal Counsel
6. North American Spine Partners With University General Hospital to Bring Back Pain Relief to Houston Patients
7. US Oncology Announces Addition of John Osborn as EVP & General Counsel and Asif Ahmad as EVP of Technology Services
8. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
9. Vanda Pharmaceuticals Adds Former U.S. Surgeon General, Steven Galson, to its Board of Directors
10. Xacore Partners With ESSE, Headed by Retired Army Four Star General, to Tackle Military Hearing Loss
11. Acuo Technologies Announces Implementation and Acceptance of Acuos DICOM Services Grid(TM) With Lancaster General Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Mass , Dec. 22, 2014 /PRNewswire/ -- RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today issued the following open letter ... Cauwenbergh , Dr. Med. Sc. Dear ... days a number of inaccurate statements posted on ...
(Date:12/22/2014)... Dec. 22, 2014 TWi Biotechnology, Inc., ... Allowance for AC-201, TWi Biotechnology,s lead drug candidate, ... China for patent application numbered ... acceptable salts, active metabolite for treatment of type ... of treatment using AC-201 for type II diabetes, ...
(Date:12/19/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB:  ADMD), ... the development of brachytherapy devices and medical isotopes ... a Life Sciences Discovery Fund (LSDF) Proof of ... is the commercialization partner.  The award was made ... titled "Optimized Injectable Radiogels for High-dose Therapy of ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3
... that Induction Chemotherapy prior to ChemoRadiotherapy significantly ... ChemoRadiotherapy alone -MADRID, May 30 The ... (TTCC) announced today that Induction Chemotherapy (IC) ... treatment paradigm defined as sequential therapy, compared ...
... Fla. , May 29 GlaxoSmithKline [NYSE: ... that the United States Food and Drug Administration,s ... to three that the ARZERRA(TM) (ofatumumab) data are ... with chronic lymphocytic leukemia (CLL) whose disease is ...
Cached Medicine Technology:Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer 2Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer 3FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab) 2FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab) 3FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab) 4FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab) 5
(Date:12/22/2014)... International efforts to combat ... are receiving further support from recent initiatives ... (NGOs) and other charitable organizations. While research ... responders, patients and others can immediately benefit ... CmTP MediDefense system , which includes ...
(Date:12/22/2014)... Physicians in China are most eagerly ... of non-Hodgkin’s lymphoma (NHL), according to a new report ... consulting firm. MabThera is the only biologic available to ... form of NHL. , According to Kantar Health’s report, ... of NHL in China has been growing and is ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Explorys, the ... additions to its leadership team: Greg Yarrington as Vice ... Engineering, and Patrick Wells as Vice President of Solutions. ... add 80 new jobs in 2015 to support client ... of its platform-as-a-service offerings, and growth of its partner ...
(Date:12/22/2014)... December 22, 2014 In recognition of ... sales to Hero Reward, a local organization that provides ... , Located on a couple hundred acres ... Program offers lodging, world class fishing, hunting, hiking, horseback ... was founded several years ago to support U.S. Service ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Xarelto ... federal panel of judges has granted a request to ... the U.S. District Court, Eastern District of Louisiana. The ... order on December 12 to transfer over 50 Xarelto ... districts to the Louisiana court for consolidation under U.S. ...
Breaking Medicine News(10 mins):Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4
... Boys are twice as,likely as girls in the ... hormone (rhGH) for growth hormone deficiency, illnesses that,affect height, ... gender,difference exists in Europe, Australia and New Zealand, but ... are treated at the same rate. This indicates,a likely ...
... Spanish . , A group of scientists from the ... of the University of Granada have found out ... to obtain inhibitors of neurogenic vasodilatation, a significant progress in migraine ... del Mar Herrador and Alejandro Fernndez Barrero , has ...
... obstetrical data management system integrates system, reliability, improves ... initiatives to help drive improved ... ... 17 Hill-Rom (NYSE:,HRC) today announced the release of an ...
... LIVINGSTON, N.J., April 17 MM2 Group, Inc.,(OTC ... Genotec Nutritionals, Inc., a New York based nutraceutical,company ... its branded,products and through custom formulations for several ... for the manufacture of,fish oil sofgels. The sofgels ...
... approach that combines comprehensive gene expression profiling with genome-wide ... to an important genetic marker that can help physicians ... and will require more aggressive treatment, a research team ... in the April 15, 2008, issue of the journal ...
... Activity, DALLAS, April 17 ACCESS ... from preclinical studies,ongoing at the prestigious Imperial ... antibody. The new data, presented by Dr.,Mahendra ... that Angiolix has unusually high accumulation in ...
Cached Medicine News:Health News:Growth Hormone is Used to Treat Twice as Many Short Boys Than Girls in the U.S. and Asia; Gender Difference is Smaller in the Rest of the World 2Health News:Growth Hormone is Used to Treat Twice as Many Short Boys Than Girls in the U.S. and Asia; Gender Difference is Smaller in the Rest of the World 3Health News:Growth Hormone is Used to Treat Twice as Many Short Boys Than Girls in the U.S. and Asia; Gender Difference is Smaller in the Rest of the World 4Health News:Scientists obtain anticancer medicines from the elecampe, a wild plant growing in the Mediterranean 2Health News:Hill-Rom's NaviCare(R) WatchChild(R) Solution Provides Enhanced Information Technology Solutions for Obstetrical Care 2Health News:MM2 Group Provides Additional Quotes for New Venture in China 2Health News:Genome analysis reveals new protein associated with breast cancer progression 2Health News:Access Pharmaceuticals Announces New Data on Angiolix(R) 2Health News:Access Pharmaceuticals Announces New Data on Angiolix(R) 3
... Thyroid-stimulating hormone (TSH) is a 32 kDa ... the anterior pituitary gland [1]. The structure ... of the pituitary and placental gonadotropins, consisting ... identical between these hormones and a unique ...
... (T4) is the primary active hormone synthesized ... gland [1]. T4 is synthesized via a ... by the follicular cells, (ii) iodination of ... to formation of 3-monoiodotyrosine and 3,5-diiodotyrosine (MIT ...
... primarily by 5-monodeioination of thyroxine (T4) in ... production occurs at a rate which is ... of T3 from the thyroid gland into ... to 80-100 micrograms/day for T4. In addition, ...
... Human Insulin-like growth factor binding protein-3 (IGFBP-3) is ... in postnatal serum, as a component of the ... IGFBP-3, a molecule of IGF-I or IGF-II and ... the actions of the IGFs. The molar concentration ...
Medicine Products: